Get the Stockscreener App
3.10
6.20%
-0.205
Clene Inc stock is traded at $3.10, with a volume of 204.44K.
It is down -6.20% in the last 24 hours and down -19.69% over the past month.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
See More
Previous Close:
$3.305
Open:
$3.39
24h Volume:
204.44K
Relative Volume:
1.87
Market Cap:
$44.06M
Revenue:
$134.00K
Net Income/Loss:
$-33.51M
P/E Ratio:
-0.9665
EPS:
-3.2074
Net Cash Flow:
$-18.15M
1W Performance:
-19.69%
1M Performance:
-19.69%
6M Performance:
-51.18%
1Y Performance:
-62.42%
1-Day Range:
$3.0152
$3.39
1-Week Range:
$3.0152
$3.93
52-Week Range:
$3.0152
$13.50
Clene Inc Stock (CLNN) Company Profile
Name
Clene Inc
Sector
Industry
Phone
801-676-9695
Address
6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY
Compare CLNN vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLNN
Clene Inc
|
3.10 | 44.06M | 134.00K | -33.51M | -18.15M | -3.2074 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Clene Inc Stock (CLNN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-18-22 | Initiated | H.C. Wainwright | Buy |
| May-02-22 | Initiated | Canaccord Genuity | Buy |
| Sep-28-21 | Initiated | Oppenheimer | Outperform |
Clene Inc Stock (CLNN) Latest News
Two parties report shared voting power over 221,660 shares in Clene (CLNN). - Stock Titan
A $4 million raise is expected to carry an ALS biotech past a potential FDA decision - Stock Titan
Insider-linked LLC acquires new Clene (CLNN) shares - Stock Titan
Clene (CLNN) CEO buys more stock in board-approved deal - Stock Titan
Insiders back new funding round at Clene Inc. (CLNN) to support lead drug filing - Stock Titan
A biotech's $4 million stock offering is expected to fund operations into 2027 - Stock Titan
Clene at cantorfitzgerald global healthcare conference: ALS drug nears filing By Investing.com - Investing.com Canada
Clene at cantorfitzgerald global healthcare conference: ALS drug nears filing By Investing.com - Investing.com India
Clene at cantorfitzgerald global healthcare conference: ALS drug nears filing By Investing.com - Investing.com UK
Clene to Present at Upcoming September Investor Conferences - Investing News Network
Clene to Present at Upcoming September Investor Conferences - manilatimes.net
Two investor conferences in New York will hear from Clene this month - Stock Titan
CLENE Q2 BASIC EPS USD -1.08 - Moomoo
Clene (CLNN) Financial Results: EPS Prints Above Forecast in the Latest Reading; Trading Move: Shares Finish 1.14% Down at the CloseNext Quarter Guidance - vinanet.vn
Analysts’ Top Consumer Goods Picks: Kimberly Clark (KMB), Clene (CLNN) - The Globe and Mail
Clene (CLNN) Outlook: Adds 4.30% to Close at $4.37 at the Close; Price Context: the Near-Term Reference Band Stretches From $4.15 to $4.59 under the Current SnapshotQuote Data - vinanet.vn
Clene Eyes Q4 NDA for ALS Drug After FDA-Requested Biomarker Analyses - MarketBeat
Clene Eyes Q4 NDA for ALS Drug After FDA-Requested Biomarker Analyses - Yahoo Finance
Clene at Emerging Growth Conference: FDA path takes shape for ALS drug - Investing.com
CLNN: CNM-Au8 shows strong survival and functional benefits in ALS, with NDA submission imminent - TradingView
Clene (CLNN) Move: Climbs 0.49% to $4.11 on the Day; Technical Setup: $3.90 and $4.32 Define the Nearby Reference Levels for the Current SessionVWAP Deviation - vinanet.vn
Presenting on Emerging Growth Conference 95 Day 1 on August 19; Register to live stream - Investing News Network
HC Wainwright Issues Negative Estimate for Clene Earnings - MarketBeat
Clene (NasdaqCM:CLNN) Stock Forecast & Analyst Predictions - simplywall.st
Clene(CLNN) Stock Options Chain | Quotes & News - Moomoo
Clene to Present at the Emerging Growth Conference - Investing News Network
Clene stock holds at buy as H.C. Wainwright keeps $31 target By Investing.com - Investing.com Australia
Clene to Present at the Emerging Growth Conference - marketscreener.com
Clene schedules a 3:10 p.m. webcast—what will it cover? - Stock Titan
Clene stock holds at buy as H.C. Wainwright keeps $31 target - Investing.com
Clene stock holds at buy as H.C. Wainwright keeps $31 target - Investing.com Australia
Clene stock holds at buy as H.C. Wainwright keeps $31 target - Investing.com Nigeria
Clene stock holds at buy as H.C. Wainwright keeps $31 target - Investing.com Canada
Clene stock holds at buy as H.C. Wainwright keeps $31 target - Investing.com
Clene to Present at the Emerging Growth Conference - The Manila Times
Clene (NASDAQ:CLNN): Why Is Evidence And Funding in Focus Today? - Kalkine Media
Clene (NASDAQ:CLNN): Why Is Clinical Evidence in Focus Today? - Kalkine Media
CLNN Looks 375.9% Overvalued on GF Value™ - GuruFocus
Clene earnings missed by $0.75, revenue topped estimates - Investing.com
Clene (NASDAQ:CLNN) Announces Quarterly Earnings Results, Misses Estimates By $0.71 EPS - MarketBeat
Clene Releases Q2 2026 Financial Results - AlphaStreet
Vivo Opportunity entities disclose 9.99% Clene Inc. (CLNN) stake via warrants - Stock Titan
Clene Inc. (CLNN) grants 3,195 stock options to director Matthew Kiernan - Stock Titan
Clene Inc. (CLNN) grants 4,872 stock options to director Alison Mosca - Stock Titan
Clene Inc. (CLNN) grants director Arjun Desai 3,674 options at $4.19 strike - Stock Titan
Clene Inc. (CLNN) director receives 6,230 stock options at $4.19 strike - Stock Titan
Clene Inc. (CLNN) awards director Shalom Jacobovitz 4,752 stock options at $4.19 - Stock Titan
Clene Inc. (CLNN) director receives 3,514 stock options vesting immediately at $4.19 - Stock Titan
Clene Inc. (CLNN) director granted 3,514 stock options at $4.19 strike - Stock Titan
Clene Q2 FY26 net loss widens 81% to $13.42 million - Bitget
Clene Inc Stock (CLNN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Clene Inc Stock (CLNN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ugwumba Chidozie | 10% Owner |
May 11 '26 |
Sale |
6.75 |
22,177 |
149,695 |
176,713 |
| Symbiosis II LLC | Former Board Member |
May 11 '26 |
Proposed Sale |
6.50 |
198,890 |
1,292,785 |
0 |
| Ugwumba Chidozie | 10% Owner |
May 04 '26 |
Sale |
6.80 |
72,884 |
495,611 |
198,890 |
| Symbiosis II LLC | Former Board Member |
May 04 '26 |
Proposed Sale |
6.55 |
41,260 |
270,381 |
0 |
| Ugwumba Chidozie | 10% Owner |
May 01 '26 |
Sale |
6.01 |
5,795 |
34,828 |
271,774 |
| Ugwumba Chidozie | 10% Owner |
Apr 30 '26 |
Sale |
6.08 |
5,736 |
34,875 |
277,569 |
| Ugwumba Chidozie | 10% Owner |
Apr 29 '26 |
Sale |
5.63 |
12,170 |
68,517 |
283,305 |
| Ugwumba Chidozie | 10% Owner |
Apr 28 '26 |
Sale |
5.90 |
1,591 |
9,387 |
295,475 |
| Symbiosis II LLC | Former Board Member |
Apr 28 '26 |
Proposed Sale |
5.90 |
56,916 |
335,804 |
0 |
| Ugwumba Chidozie | 10% Owner |
Apr 21 '26 |
Sale |
6.14 |
61,345 |
376,658 |
297,066 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):